Talphera, Inc. is a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings. Talphera’s lead product candidate, Niyad is a lyophilized formulation of nafamostat and is currently being studied under an investigational device exemption, or IDE, as an anticoagulant for the extracorporeal circuit, and has received Breakthrough Device Designation Status from the FDA. Talphera is also developing two pre-filled syringes in-licensed from its partner Aguettant: Fedsyra™, a pre-filled ephedrine syringe, and PFS-02, a pre-filled phenylephrine syringe.
To learn more about the development status of these product candidates, please visit our website at www.talphera.com.
Company Details
- Employees
- 37
- Founded
- -
- Address
- 1850 Gateway Dr, San Mateo,california 94404,united States
- Phone
- 650-216-6500
- in****@****lrx.com
- Industry
- Pharmaceutical Manufacturing
- NAICS
-
Pharmaceutical and Medicine ManufacturingMedicinal and Botanical ManufacturingPharmaceutical Preparation ManufacturingIn-Vitro Diagnostic Substance ManufacturingBiological Product (except Diagnostic) Manufacturing
- Website
- acelrx.com
- HQ
- San Mateo, California
Talphera, Inc. Questions
Talphera, Inc.'s helpline number is 650-216-6500
Talphera, Inc.'s website is acelrx.com
Talphera, Inc.'s LinkedIn profile is https://www.linkedin.com/company/acelrx-pharmaceuticals
Talphera, Inc. has
37 employees.
View email and phone details for 37
employees at Talphera, Inc..
Talphera, Inc.'s industry is
Pharmaceutical Manufacturing
Talphera, Inc.'s top competitors are
Korro Bio, Inc.,
Gsk,
Mirum Pharmaceuticals, Inc.,
Adamas Pharmaceuticals, Inc.,
Inizio Engage,
Angiocrine Bioscience, Inc.,
Pharmabcine Inc.,
Amyris,
Atyr Pharma,
Akebia Therapeutics.
Talphera, Inc.'s support email address is info@acelrx.com
Talphera, Inc.'s categories are Pharmaceutical Manufacturing
Talphera, Inc.'s founding year is 2005
